16 March 2020
: Case report
A Rare, Yet Treatable Pancreatic Tumor: Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma
Rare disease
John Xie1ABCDEF*, Elizabeth Rinker2BE, Mazen Zaarour3ADEDOI: 10.12659/AJCR.921269
Am J Case Rep 2020; 21:e921269
Abstract
BACKGROUND: Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) is a rare subtype of B-cell neoplasm that can have diverse presentations. When it involves the pancreas (i.e., pancreatic lymphoma), it can mimic metastatic pancreatic adenocarcinoma. Pancreatic lymphoma and adenocarcinoma often have similar clinical, laboratory, and radiographic features making the distinction challenging without pathological tissue examination. The differentiation of these 2 entities is important as the prognosis of pancreatic lymphoma is certainly more favorable with a chance of cure with chemoimmunotherapy.
CASE REPORT: We present an unusual case of EBV-positive DLBCL involving the pancreas that was initially believed to be metastatic pancreatic adenocarcinoma. The patient was treated with chemoimmunotherapy and had a remarkable response. This is the first known case of EBV-positive DLBCL involving the pancreas that was successfully treated with chemoimmunotherapy.
CONCLUSIONS: EBV-positive DLBCL can have diverse presentations, including a pancreatic mass with multi-organ involvement, which mimics metastatic pancreatic adenocarcinoma. The prognosis of EBV-positive DLBCL is thought to be worse than that of EBV-negative tumors. However, it remains certainly superior to that of its adenocarcinoma counterpart with conventional chemoimmunotherapy.
Keywords: Epstein-Barr Virus Infections, Lymphoma, Large B-Cell, Diffuse, Pancreatic Neoplasms, Combined Modality Therapy, Diagnosis, Differential, Drug Therapy, Immunotherapy
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947163
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949194
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948731
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947386
Most Viewed Current Articles
21 Jun 2024 : Case report
101,839
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
54,458
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
38,088
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
25,936
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200